At the end of weeks 2, 4, and 6 of the study, all the shipments received during that time period were inspected. A total of 32 batches were received during each 2 wk interval (i.e., four from each of the eight pharmacies). Two of the authors opened each package and verified that the product label matched the capsule size requested. The 30 capsules were then placed in a standard pharmaceutical vial that was coded with a randomly generated numerical identifier. Correct identification of each batch was verified by both authors.
Introduction
Trilostane is a synthetic steroid analog that competitively inhibits 3-a-hydroxysteroid dehydrogenase. This enzyme facilitates the conversion of pregnenolone and 17-er-hydroxypregnenolone to progesterone and 17-er-hydroxyprogesterone, respectively, and is required for the synthesis of cortisol by the adrenal cortex.1
Trilostane has been widely used in Europe and Australia for many years for the management of dogs with hyperadrenocorticism (HAG) due to either a pituitary adenoma or a functional adrenal cortical tumor and was approved for use in dogs with both forms of HAG in the United States in 2oo8.2r4
Prior to approval by the US Food and Drug Administration (FDA) , compounded trilostane products were marketed to veterinarians through internet sites, at professional conferences, and by direct mailing. Although reformulation of the licensed product is
Evaluation of Compounded Trilostane Products
The goal of this study was to investigate the pharmaceutical properties of commercially available compounded trilostane products and to compare the compounded products with trilostane reformulated in-house from the licensed product, as well as the proprietary product itself. The hypothesis was that clinically significant variations in trilostane content, purity and dissolution characteristics would be documented in products purchased from compounding pharmacies.
Materials and Methods
An internet search was conducted to identify eight pharmacies marketing compounded trilostane productsa-h. Two orders for different capsule sizes of trilostane were faxed to each pharmacy every week for 6 wk starting in September 2009. Each request was for 30 capsules containing 15 mg, 45 mg, or 100 mg of trilostane (i.e., sizes that are not currently licensed). Over the study period, each pharmacy supplied four batches of each size. The compounded products were shipped to the pharmacy at Texas A&M Veterinary Medical Teaching Hospital and stored at room ternperature until prepared for analysis.
At the end of weeks 2, 4, and 6 of the study, all the shipments received during that time period were inspected. A total of 32 batches were received during each 2 wk interval (i.e., four from each of the eight pharmacies). Two of the authors opened each package and verified that the product label matched the capsule size requested. The 30 capsules were then placed in a standard pharmaceutical vial that was coded with a randomly generated numerical identifier. Correct identification of each batch was verified by both authors.
At the start of the study, one of the investigators (CDN, a licensed pharmacist) prepared 120 capsules containing only inert filler± and 120 capsules containing 15 mg of the licensed productj.
These capsules were made using a pharmaceutical balancek and standard pharmaceutical techniques. These were divided into batches (each containing 30 capsules) and packaged and coded in the same manner as the compounded products. The compounded controls (CCs) were used to validate the integrity of the analytic process and to investigate the impact of reformulation on the proprietary drug. Four batches of proprietary capsules (PCs) in 30 mg and 60 mg sizes were similarly packaged and coded.
At the end of every 2 wk interval during the study period, 32 repackaged batches of purchased compounded products together with two or three CC batches (0 mg and/or 15 mg) and two or three PC batches (30 mg and/or 60 mg) were submitted for analysis.
Each shipment contained four batches of various sizes from each compounding pharmacy to limit the impact of inter-assay variation. Analysis was performed at a pharmaceutical manufacturing facilit)I compliant with the FDA's current Good Manufacturing Practice regulations and approved by the Medicines and Healthcare products Regulatory Agency of the UK.6'7 None of the authors, of this report had any involvement in the analytic process, and all personnel at the testing facility were blinded to the source of the capsules. The 0 mg and 15 mg CCs were indistinguishable from the purchased compounded products; however, the 30 mg and 60 mg PCs were easily recognizable due to the imprint on the capsule shells. Information was provided about the label claim for each batch because this was necessary for the analytical process.
The 0 mg capsules intentionally mislabeled as containing 15 mg.
Upon receipt at the testing facility, 10 capsules from each batch were emptied and tested for weight variation. The contents of the 10 capsules were subsequently blended together to form a homogeneous composite. Based on the expected total weight of trilostane in the 10 capsule composite, two or three aliquots were weighed out, each with a presumed trilostane content equivalent to the weight of the standard used for comparison. Each sample was then sonicated in methanol in preparation for the analytic process. 
Discussion
In the last few years, trilostane has become a standard therapy for dogs with HAG. One product was approved for use in the US in late 
